New hope for hard-to-treat lymphoma: experimental drug targets cancer cells

NCT ID NCT05296070

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This study tests a drug called loncastuximab tesirine in 50 adults with marginal zone lymphoma that has returned or not responded to prior therapy. The drug is designed to deliver a toxin directly to cancer cells. Researchers will measure how many participants achieve complete remission (cancer disappearance) at 6 and 12 months, and track side effects. This is an open-label, phase 2 trial, meaning all participants receive the drug and the focus is on safety and effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vanderbilt University

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.